People With Certain Flu-Like
Diseases To Be Quarantined
Under New Bush Executive Order

From Patricia Doyle, PhD
Hello Jeff - A special thanks to PEP, Pat, for providing this information on my message board.
Patricia Doyle
Certain Flu-Like Diseases To Be Quarantined Under New Bush Executive Order
I hope the date of this order is not significant. Just don't get into any white boxcars - especially the ones without windows... --Pat
For Immediate Release
Office of the Press Secretary
April 1, 2005
Executive Order: Amendment to E.O. 13295
Relating to Certain Influenza Viruses and Quarantinable Communicable Diseases
By the authority vested in me as President by the Constitution and the laws of the United States of America, including section 361(b) of the Public Health Service Act (42 U.S.C. 264(b)), it is hereby ordered as follows:
Section 1. Based upon the recommendation of the Secretary of Health and Human Services, in consultation with the Surgeon General, and for the purpose set forth in section 1 of Executive Order 13295 of April 4, 2003, section 1 of such order is amended by adding at the end thereof the following new subsection:
"(c) Influenza caused by novel or re-emergent influenza viruses that are causing, or have the potential to cause, a pandemic.".
Sec. 2. This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, entities, officers, employees or agents, or any other person.
April 1, 2005.
Post Extras:
Reged: 04/11/03
Posts: 671
Loc: England
Contract awarded to Develop Influenza Vaccines
#2820 - 04/04/05 08:15 AM (
How very convenient - at the same time as the order to quarantine, a contract is awarded to develop vaccines. Using cell based method - which definitely relies on none of the experiments escaping accidentally! But we feel safe with that - don't we.......... Pat
News Release
Friday, April 1, 2005
HHS Press Office
(202) 690-6343
HHS Awards $97 Million Contract to Develop Cell Culture-Based Influenza Vaccine Effort Designed to Diversify and Accelerate Vaccine Production to Enhance Pandemic Preparedness
HHS Secretary Mike Leavitt announced today that the Department has awarded a $97 million contract to Sanofi Pasteur to speed the production process for new influenza vaccines for the U.S. The five-year award supports the development of advanced techniques using a cell-based, rather than an egg-based, approach to producing influenza vaccines. The contract also calls for plans to establish a U.S.-based, cell cultured influenza vaccine manufacturing facility.
"This action begins the process of speeding up influenza vaccine production, improving surge capacity and scaling up U.S. manufacturing capability," Secretary Leavitt said. "As a result, this should allow the U.S. to have influenza vaccines in a more timely, less laborious manner, and it provides another tool for responding to and controlling a global influenza pandemic."
Currently licensed influenza vaccines are produced in chicken eggs in a process that takes nearly nine months. Scientists must first select the virus strains that they anticipate will be the predominant strains circulating in the U.S. during the following season. These strains are then adapted to grow in eggs. Manufacturers inject each adapted virus strain separately into millions of fertilized eggs, which are subsequently incubated to produce influenza virus. Large batches of these eggs are harvested and blended into a single vaccine product that includes all three influenza virus strains.
Using a cell culture approach to producing influenza vaccine offers a number of benefits. Vaccine manufacturers can bypass the step needed to adapt the virus strains to grow in eggs. In addition, cell culture-based influenza vaccines will help meet surge capacity needs in the event of a shortage or pandemic, since cells may be frozen in advance and large volumes grown quickly. U.S. licensure and manufacture of influenza vaccines produced in cell culture also will provide security against risks associated with egg-based production, such as the potential for egg supplies to be contaminated by various poultry-based diseases. Finally, the new cell-based influenza vaccines will provide an option for people who are allergic to eggs and therefore unable to receive the currently licensed vaccines.
Cell-based influenza vaccines use mammalian cells to grow the influenza viruses used in the vaccine. Under this contract, Sanofi Pasteur, a part of the Sanofi Pasteur Group, will develop, scale-up, and manufacture clinical investigational lots of inactivated influenza vaccines using human cells. These vaccines will be tested in human clinical trials in adult, elderly, and pediatric populations within the U.S. In addition, Sanofi Pasteur will develop plans for a U.S. manufacturing facility capable of producing at least 300 million doses of a pandemic influenza vaccine using this technology.
This contract is one of several contracts that HHS has awarded during the past year to enhance pandemic influenza preparedness and the annual influenza vaccine supply. Earlier awards were made to increase domestic influenza vaccine capacity, secure year round vaccine raw materials and supplies, and develop pandemic-like vaccine candidates for clinical evaluation.
This contract follows the August 2004 release of the draft National Pandemic Influenza Preparedness and Response Plan, which outlines a coordinated national strategy to prepare for and respond to an influenza pandemic. The draft plan may be found online at and is a result of years of work by the Department.
Note: All HHS press releases, fact sheets and other press materials are available at
Last revised: April 1, 2005
The White House | FirstGov
U.S. Department of Health & Human Services · 200
Independence Avenue, S.W. · Washington, D.C.
Patricia A. Doyle, PhD
Please visit my "Emerging Diseases" message
Zhan le Devlesa tai sastimasa
Go with God and in Good Health



This Site Served by TheHostPros